MediPharm Labs Corp. Logo

MediPharm Labs Corp.

MEDIF

(2.0)
Stock Price

0,04 USD

-22.58% ROA

-24.41% ROE

-2.11x PER

Market Cap.

28.735.455,18 USD

4.24% DER

0% Yield

-30.56% NPM

MediPharm Labs Corp. Stock Analysis

MediPharm Labs Corp. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

MediPharm Labs Corp. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.44x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (5%), which means it has a small amount of debt compared to the ownership it holds

3 Revenue Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

4 Net Profit Growth

This company's net profit has been consistently on the rise over the past three years, indicating a strong financial performance and making it an appealing investment opportunity.

5 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

6 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (1), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

7 ROE

Negative ROE (-33.54%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

8 ROA

The stock's ROA (-26.45%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

9 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

10 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

11 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

MediPharm Labs Corp. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

MediPharm Labs Corp. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

MediPharm Labs Corp. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

MediPharm Labs Corp. Revenue
Year Revenue Growth
2017 0
2018 10.198.000 100%
2019 129.252.000 92.11%
2020 36.012.000 -258.91%
2021 21.711.000 -65.87%
2022 22.117.000 1.84%
2023 34.020.000 34.99%
2023 33.061.999 -2.9%
2024 39.084.000 15.41%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

MediPharm Labs Corp. Research and Development Expenses
Year Research and Development Expenses Growth
2017 0
2018 261.000 100%
2019 867.000 69.9%
2020 2.225.000 61.03%
2021 1.355.000 -64.21%
2022 1.002.000 -35.23%
2023 244.000 -310.66%
2023 209.000 -16.75%
2024 188.000 -11.17%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

MediPharm Labs Corp. General and Administrative Expenses
Year General and Administrative Expenses Growth
2017 0
2018 5.543.000 100%
2019 30.859.000 82.04%
2020 24.585.000 -25.52%
2021 18.402.000 -33.6%
2022 18.453.000 0.28%
2023 18.800.000 1.85%
2023 21.635.000 13.1%
2024 20.668.000 -4.68%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

MediPharm Labs Corp. EBITDA
Year EBITDA Growth
2017 0
2018 -7.095.000 100%
2019 9.955.000 171.27%
2020 -59.948.000 116.61%
2021 -37.151.000 -61.36%
2022 -25.440.000 -46.03%
2023 -14.256.000 -78.45%
2023 -16.353.000 12.82%
2024 -12.216.000 -33.87%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

MediPharm Labs Corp. Gross Profit
Year Gross Profit Growth
2017 0
2018 3.967.000 100%
2019 42.914.000 90.76%
2020 -43.978.000 197.58%
2021 -15.246.000 -188.46%
2022 -1.914.000 -696.55%
2023 9.668.000 119.8%
2023 4.213.999 -129.43%
2024 10.796.000 60.97%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

MediPharm Labs Corp. Net Profit
Year Net Profit Growth
2017 0
2018 -8.386.000 100%
2019 1.131.000 841.47%
2020 -67.110.000 101.69%
2021 -54.801.000 -22.46%
2022 -29.983.000 -82.77%
2023 -17.308.000 -73.23%
2023 -13.083.000 -32.29%
2024 -14.444.000 9.42%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

MediPharm Labs Corp. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2017 0
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

MediPharm Labs Corp. Free Cashflow
Year Free Cashflow Growth
2018 -25.685.000
2019 -57.703.000 55.49%
2020 -45.276.000 -27.45%
2021 -13.996.000 -223.49%
2022 -16.932.000 17.34%
2023 -12.234.000 -38.4%
2023 -3.492.000 -250.34%
2024 -1.344.000 -159.82%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

MediPharm Labs Corp. Operating Cashflow
Year Operating Cashflow Growth
2018 -11.113.000
2019 -25.265.000 56.01%
2020 -37.773.000 33.11%
2021 -13.213.000 -185.88%
2022 -16.069.000 17.77%
2023 -11.763.000 -36.61%
2023 -3.232.000 -263.95%
2024 -1.323.000 -144.29%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

MediPharm Labs Corp. Capital Expenditure
Year Capital Expenditure Growth
2018 14.572.000
2019 32.438.000 55.08%
2020 7.503.000 -332.33%
2021 783.000 -858.24%
2022 863.000 9.27%
2023 471.000 -83.23%
2023 260.000 -81.15%
2024 21.000 -1138.1%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

MediPharm Labs Corp. Equity
Year Equity Growth
2017 400.000
2018 27.843.000 98.56%
2019 131.227.000 78.78%
2020 78.414.000 -67.35%
2021 83.146.000 5.69%
2022 56.005.000 -48.46%
2023 53.005.000 -5.66%
2023 55.203.000 3.98%
2024 49.855.000 -10.73%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

MediPharm Labs Corp. Assets
Year Assets Growth
2017 400.000
2018 42.729.000 99.06%
2019 168.830.000 74.69%
2020 118.231.000 -42.8%
2021 92.361.000 -28.01%
2022 65.495.000 -41.02%
2023 63.937.000 -2.44%
2023 68.007.000 5.98%
2024 61.245.000 -11.04%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

MediPharm Labs Corp. Liabilities
Year Liabilities Growth
2017 0
2018 14.886.000 100%
2019 37.603.000 60.41%
2020 39.817.000 5.56%
2021 9.215.000 -332.09%
2022 9.490.000 2.9%
2023 10.932.000 13.19%
2023 12.804.000 14.62%
2024 11.390.000 -12.41%

MediPharm Labs Corp. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.09
Net Income per Share
-0.03
Price to Earning Ratio
-2.11x
Price To Sales Ratio
0.78x
POCF Ratio
-2.74
PFCF Ratio
-2.63
Price to Book Ratio
0.57
EV to Sales
0.38
EV Over EBITDA
-0.87
EV to Operating CashFlow
-1.33
EV to FreeCashFlow
-1.27
Earnings Yield
-0.47
FreeCashFlow Yield
-0.38
Market Cap
0,03 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0.31
Graham NetNet
0.04

Income Statement Metrics

Net Income per Share
-0.03
Income Quality
0.77
ROE
-0.25
Return On Assets
-0.21
Return On Capital Employed
-0.27
Net Income per EBT
0.98
EBT Per Ebit
0.99
Ebit per Revenue
-0.31
Effective Tax Rate
-0.04

Margins

Sales, General, & Administrative to Revenue
0.66
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0.06
Gross Profit Margin
0.29
Operating Profit Margin
-0.31
Pretax Profit Margin
-0.31
Net Profit Margin
-0.31

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.03
Free CashFlow per Share
-0.03
Capex to Operating CashFlow
0.04
Capex to Revenue
-0.01
Capex to Depreciation
-0.17
Return on Invested Capital
-0.36
Return on Tangible Assets
-0.23
Days Sales Outstanding
63.73
Days Payables Outstanding
45.48
Days of Inventory on Hand
123.82
Receivables Turnover
5.73
Payables Turnover
8.03
Inventory Turnover
2.95
Capex per Share
-0

Balance Sheet

Cash per Share
0,04
Book Value per Share
0,12
Tangible Book Value per Share
0.12
Shareholders Equity per Share
0.12
Interest Debt per Share
0.01
Debt to Equity
0.04
Debt to Assets
0.03
Net Debt to EBITDA
0.93
Current Ratio
3.07
Tangible Asset Value
0,05 Bil.
Net Current Asset Value
0,02 Bil.
Invested Capital
0.04
Working Capital
0,02 Bil.
Intangibles to Total Assets
0.02
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
9876000
Debt to Market Cap
0.07

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

MediPharm Labs Corp. Dividends
Year Dividends Growth

MediPharm Labs Corp. Profile

About MediPharm Labs Corp.

MediPharm Labs Corp., a pharmaceutical company, produces and sells pharmaceutical-quality cannabis oil and concentrates, and advanced derivative products in Canada, Australia, Germany, and internationally. It formulates, processes, packages, and distributes cannabis extracts and advanced cannabinoid-based products. The company also provides GMP flower sourcing, packaging, and distribution services. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada.

CEO
Mr. David A. Pidduck
Employee
166
Address
151 John Street
Barrie, L4N 2L1

MediPharm Labs Corp. Executives & BODs

MediPharm Labs Corp. Executives & BODs
# Name Age
1 Mr. Keith Strachan
Co-Founder & President
70
2 Mr. Brett Moon
Vice President of Sales
70
3 Mr. Patrick McCutcheon
Founder
70
4 Mr. Kirk Binns
Executive Vice President of Global Accounts
70
5 Mr. David A. Pidduck
Chief Executive Officer & Director
70
6 Mr. Greg Hunter
Chief Financial Officer
70

MediPharm Labs Corp. Competitors